Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 7,767 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of COR388

NCT03418688
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388, Placebo
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Role of Sleep in the Treatment of Cannabis Use Disorders

NCT01685073
View directory record Official record
Conditions
Drug Addiction
Interventions
Zolpidem extended-release, MET/CBT
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

NCT00506441
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196, Placebo
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Glendale, Arizona • Tempe, Arizona • Hot Springs, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

NCT00595231
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SYN111, Placebo
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Atlanta, Georgia • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 1Phase 2 Interventional

Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

NCT00380302
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AVE1625
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2008 · Synced Oct 14, 2026, 8:19 AM EDT
Terminated Phase 3 Interventional Results available

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

NCT01257802
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse
Interventions
depot leuprolide acetate 3.75 mg, Placebo
Drug
Lead sponsor
Joseph Mccune
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 14, 2026, 8:19 AM EDT
Suspended Phase 2 Interventional

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

NCT04197102
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
CBD Isolate, CBD Broad Spectrum, Placebo oil
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Treatment of Childhood Social Phobia

NCT00043537
View directory record Official record
Conditions
Social Phobia
Interventions
Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo
Behavioral · Drug
Lead sponsor
University of Central Florida
Other
Eligibility
8 Years to 16 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
University of Maryland, College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder

NCT03418623
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
GET73, Placebo
Drug · Other
Lead sponsor
Laboratorio Farmaceutico Ct S.r.l.
Industry
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

NCT05569759
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
zetomipzomib, placebo, zetomipzomib in open-label extension
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 14, 2026, 8:19 AM EDT
Recruiting Phase 2 Interventional

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

NCT06136546
View directory record Official record
Conditions
Depressive Disorder, Major, Inflammation
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dry Eye Disease Study With Brimonidine

NCT03418727
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 14, 2026, 8:19 AM EDT
Suspended Phase 2 Interventional

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

NCT03325322
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Fisetin, Placebo oral capsule
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

NCT01207622
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Substance Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

NCT04524351
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00093951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SGS742
Drug
Lead sponsor
Saegis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

NCT01114672
View directory record Official record
Conditions
Pruritis
Interventions
50,000 Units Ergocalciferol, Placebo
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bethpage, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 14, 2026, 8:19 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

NCT03533556
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-theanine, Caffeine, L-theanine-Caffeine Combination, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 14, 2026, 8:19 AM EDT